ASP-543 (also known as YM-543), a selective inhibitor of the sodium-glucose cotransporter 2. This protein is specifically expressed in the kidney that plays an important role in renal glucose reabsorption, and its inhibition may present a novel therapeutic strategy for treating diabetes. ASP-543 participated in phase II clinical trials in Europe and in the USA for the treatment of Type 2 diabetes mellitus but these studies were discontinued.

AT-9283 was being developed by Astex Pharmaceuticals as a treatment for cancer and myelofibrosis. AT-9283 is an inhibitor of mitosis (cell division) and is the second most progressed drug candidate in the Astex portfolio of novel molecularly targeted cancer drugs. All of Astex’s current products have been discovered internally using its proprietary drug discovery approach. AT9283 is a potent inhibitor of the Aurora A and B kinases and has been shown to arrest tumour growth in a range of tumour models. Aurora kinases play a key role in mitotic checkpoint control in cell division. Both Aurora A and B are over-expressed in many human tumours and are believed to be excellent targets for anti-cancer therapy.

OSI-930 (now SIM-930) is a potent, oral small-molecule receptor tyrosine kinase inhibitor, which acts predominantly against VEGF receptors (VEGFR), c-Kit, and platelet-derived growth factor receptors. OSI-930 has a pharmacokinetic-pharmacodynamic profile distinct from other RTK inhibitors, with potent antitumor activity in multiple xenograft models. OSI-930 passed through phase I clinical trial in the USA (in patients with advanced solid tumors) and recieved the clinical approval by China FDA after being out-licensed to Simcere Pharma in China.